|
JP2020109115A
|
|
Emulsion comprising nk-1 receptor antagonist
|
|
CA3111570A1
|
|
Post-surgical pain treatment
|
|
AU2019214872A1
|
|
Method of administering emulsion formulations of an NK-1 receptor antagonist
|
|
WO2018013493A1
|
|
Powered delivery device
|
|
US2017340740A1
|
|
Long-acting polymeric delivery systems comprising olanzapine and a 5-ht3 receptor antagonist
|
|
US2017035888A1
|
|
Long-acting polymeric delivery systems
|
|
EP3509601A1
|
|
A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
|
|
KR20180118136A
|
|
Emulsions containing NK-1 receptor antagonists
|
|
US2017216205A1
|
|
Emulsion formulations of an NK-1 receptor antagonist and uses thereof
|
|
US2016082013A1
|
|
Emulsion formulations of aprepitant
|
|
EP3134070A1
|
|
Compositions of a polyorthoester and an organic acid excipient
|
|
BR112016024665A2
|
|
long acting polymeric release systems
|
|
EP3089742A1
|
|
Polymer-based compositions for extended release of proteins
|
|
US2014323517A1
|
|
Compositions and methods for injection of a biodegradable polymer-based delivery system
|
|
CN111956598A
|
|
Composition of polyorthoester and aprotic solvent
|
|
US2015359897A1
|
|
Method of treating patients non-responsive to palonosetron
|
|
US2015320866A1
|
|
Pharmaceutical composition comprising antiemetic compounds and polyorthoester
|
